It was reported yesterday that Samsung Bioepis Co Ltd, a biopharmaceutical company, has signed a new commercialisation agreement with United States-based Biogen (Nasdaq: BIIB).
The contract has been signed for two biosimilar candidates under development by Samsung Bioepis, SB11 (ranibizumab) and SB15 (aflibercept), in the United States, Canada, Europe, Japan, and Australia.
SB11 is a biosimilar candidate referencing LUCENTIS (ranibizumab) and is currently undergoing a phase three clinical trial, while SB15 is a biosimilar candidate referencing EYLEAiii (aflibercept) and is in pre-clinical development.
The contract also offers Biogen an option to extend the commercialisation term for Samsung Bioepis' three anti-TNF biosimilars, BENEPALI (etanercept), FLIXABI (infliximab), and IMRALDI (adalimumab) in Europe for an additional five years beyond its original ten-year contract. It also offers Biogen an option to receive commercialisation rights to BENEPALI, FLIXABI and IMRALDI in China in exchange for royalties on sales in the market.
Tyra Biosciences doses first patient in TYRA-300 Phase 2 study for bladder cancer
argenx advances ARGX-119 to registrational study for congenital myasthenic syndromes
hVIVO supports Cidara Therapeutics' positive Phase 2b influenza study results
Sanofi's riliprubart receives orphan drug designation in Japan for CIDP
HUTCHMED gains China approval for ORPATHYS and TAGRISSO combination in lung cancer
Hikma Pharmaceuticals USA announces USD1bn of new US investment
UCB reports positive Phase 3 results for fenfluramine in CDKL5 deficiency disorder